{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:29:20Z","timestamp":1794004160420,"version":"4.8.0"},"reference-count":331,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["20720220006"],"award-info":[{"award-number":["20720220006"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["20720220004"],"award-info":[{"award-number":["20720220004"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFC2301404"],"award-info":[{"award-number":["2021YFC2301404"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"CAMS Innovation Fund for Medical Sciences","doi-asserted-by":"publisher","award":["2019RU022"],"award-info":[{"award-number":["2019RU022"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81991491"],"award-info":[{"award-number":["81991491"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ijbiomac.2025.145501","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T19:09:51Z","timestamp":1750792191000},"page":"145501","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"P3","title":["Advancing mRNA vaccines: A comprehensive review of design, delivery, and efficacy in infectious diseases"],"prefix":"10.1016","volume":"319","author":[{"given":"Yihan","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciying","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuzhi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningshao","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaowei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ijbiomac.2025.145501_bb0005","article-title":"COVID-19 vaccine hesitancy worldwide: a concise systematic review of vaccine acceptance rates","volume":"9","author":"Sallam","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"Pt 7","key":"10.1016\/j.ijbiomac.2025.145501_bb0010","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1099\/jmm.0.039180-0","article-title":"The current challenges for vaccine development","volume":"61","author":"Oyston","year":"2012","journal-title":"J. Med. Microbiol."},{"issue":"34","key":"10.1016\/j.ijbiomac.2025.145501_bb0015","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1016\/j.vaccine.2015.04.040","article-title":"Strategies for addressing vaccine hesitancy - a systematic review","volume":"33","author":"Jarrett","year":"2015","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.145501_bb0020","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.4161\/hv.24657","article-title":"Vaccine hesitancy: an overview","volume":"9","author":"Dube","year":"2013","journal-title":"Hum. Vaccin. Immunother."},{"issue":"18","key":"10.1016\/j.ijbiomac.2025.145501_bb0025","doi-asserted-by":"crossref","first-page":"7057","DOI":"10.1093\/nar\/12.18.7057","article-title":"Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs","volume":"12","author":"Krieg","year":"1984","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.145501_bb0030","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Kariko","year":"2005","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb0035","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40364-023-00449-w","article-title":"Advances of mRNA vaccine in tumor: a maze of opportunities and challenges","volume":"11","author":"Yuan","year":"2023","journal-title":"Biomark. Res."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.145501_bb0040","first-page":"491","article-title":"mRNA vaccines: past, present, future","volume":"17","author":"Karam","year":"2022","journal-title":"Asian J Pharm Sci"},{"key":"10.1016\/j.ijbiomac.2025.145501_bb0045","author":"Bayer"},{"key":"10.1016\/j.ijbiomac.2025.145501_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.679344","article-title":"From COVID-19 to cancer mRNA vaccines: moving from bench to clinic in the vaccine landscape","volume":"12","author":"Chakraborty","year":"2021","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.145501_bb0055","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/17460441.2021.1935859","article-title":"An overview of rational design of mRNA-based therapeutics and vaccines","volume":"16","author":"To","year":"2021","journal-title":"Expert Opin. Drug Discovery"},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.145501_bb0060","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb0065","first-page":"11","article-title":"Delivery strategies for mRNA vaccines","volume":"36","author":"Ramachandran","year":"2022","journal-title":"Pharmaceut Med"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.145501_bb0070","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s11427-022-2230-4","article-title":"Current progress in the development of prophylactic and therapeutic vaccines","volume":"66","author":"Li","year":"2023","journal-title":"Sci. China Life Sci."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.145501_bb0075","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/j.ymthe.2022.02.016","article-title":"COVID-19 mRNA vaccines: platforms and current developments","volume":"30","author":"Szabo","year":"2022","journal-title":"Mol. Ther."},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.145501_bb0080","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/s41587-022-01491-z","article-title":"Unlocking the promise of mRNA therapeutics","volume":"40","author":"Rohner","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2025.145501_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2020.144640","article-title":"The combined influence of codon composition and tRNA copy number regulates translational efficiency by influencing synonymous nucleotide substitution","volume":"745","author":"Victor","year":"2020","journal-title":"Gene"},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.145501_bb0090","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.tibtech.2004.04.006","article-title":"Codon bias and heterologous protein expression","volume":"22","author":"Gustafsson","year":"2004","journal-title":"Trends Biotechnol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.145501_bb0095","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.molmed.2019.10.002","article-title":"Tailoring mRNA vaccine to balance innate\/adaptive immune response","volume":"26","author":"Linares-Fernandez","year":"2020","journal-title":"Trends Mol. Med."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.145501_bb0100","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb0105","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-37786-1","article-title":"High-throughput identification of prefusion-stabilizing mutations in SARS-CoV-2 spike","volume":"14","author":"Tan","year":"2023","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.145501_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0040180","article-title":"High guanine and cytosine content increases mRNA levels in mammalian cells","volume":"4","author":"Kudla","year":"2006","journal-title":"PLoS Biol."},{"key":"10.1016\/j.ijbiomac.2025.145501_bb0115","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.49708","article-title":"GC content shapes mRNA storage and decay in human cells","volume":"8","author":"Courel","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.ijbiomac.2025.145501_bb0120","unstructured":"M.A. Budzinska, T.E. Leonard, R.Y. Chang, N. Chaudhary, S.W. Cheetham, T.R. Mercer, H.M. Gunter, <em>mRNArchitect<\/em>: optimized design of mRNA sequences, bioRxiv (2024) 2024.12.03.626696."},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.145501_bb0125","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1016\/j.jmb.2020.01.011","article-title":"TissueCoCoPUTs: novel human tissue-specific codon and codon-pair usage tables based on differential tissue gene expression","volume":"432","author":"Kames","year":"2020","journal-title":"J. Mol. Biol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.145501_bb0130","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"issue":"48","key":"10.1016\/j.ijbiomac.2025.145501_bb0135","doi-asserted-by":"crossref","first-page":"24075","DOI":"10.1073\/pnas.1908052116","article-title":"mRNA structure regulates protein expression through changes in functional half-life","volume":"116","author":"Mauger","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7978","key":"10.1016\/j.ijbiomac.2025.145501_bb0140","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s41586-023-06127-z","article-title":"Algorithm for optimized mRNA design improves stability and immunogenicity","volume":"621","author":"Zhang","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2025.145501_bb0145","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1146\/annurev.cellbio.14.1.399","article-title":"Control of translation initiation in animals","volume":"14","author":"Gray","year":"1998","journal-title":"Annu. Rev. Cell Dev. Biol."},{"issue":"1\u20132","key":"10.1016\/j.ijbiomac.2025.145501_bb0150","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/ten.tea.2017.0485","article-title":"Maximizing the translational yield of mRNA therapeutics by minimizing 5 \u2019-UTRs","volume":"25","author":"Trepotec","year":"2019","journal-title":"Tissue Eng Pt A"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.145501_bb0155","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/0022-2836(87)90418-9","article-title":"At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells","volume":"196","author":"Kozak","year":"1987","journal-title":"J. Mol. Biol."},{"issue":"22","key":"10.1016\/j.ijbiomac.2025.145501_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2024.168804","article-title":"Rational design of untranslated regions to enhance gene expression","volume":"436","author":"Liu","year":"2024","journal-title":"J. Mol. Biol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.145501_bb0165","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/nrm.2017.103","article-title":"Functional 5\u2019 UTR mRNA structures in eukaryotic translation regulation and how to find them","volume":"19","author":"Leppek","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb0170","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1038\/s41467-024-48247-8","article-title":"5\u2019UTR G-quadruplex structure enhances translation in size dependent manner","volume":"15","author":"Lee","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb0175","doi-asserted-by":"crossref","first-page":"48","DOI":"10.14348\/molcells.2023.0003","article-title":"3\u2019UTR diversity: expanding repertoire of RNA alterations in human mRNAs","volume":"46","author":"Hong","year":"2023","journal-title":"Mol. Cells"},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.145501_bb0180","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1128\/MCB.01445-06","article-title":"A plus U-rich instability elements differentially activate 5 \u2019-3 \u2019 and 3 \u2019-5 \u2019 mRNA decay","volume":"27","author":"Murray","year":"2007","journal-title":"Mol. Cell. Biol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.145501_bb0185","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.gde.2011.03.002","article-title":"Coordinate regulation of mRNA decay networks by GU-rich elements and CELF1","volume":"21","author":"Vlasova-St Louis","year":"2011","journal-title":"Curr. Opin. Genet. Dev."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.145501_bb0190","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrg2936","article-title":"Gene silencing by microRNAs: contributions of translational repression and mRNA decay","volume":"12","author":"Huntzinger","year":"2011","journal-title":"Nat. Rev. Genet."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb0195","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13059-024-03186-x","article-title":"Structured 3\u2019 UTRs destabilize mRNAs in plants","volume":"25","author":"Zhang","year":"2024","journal-title":"Genome Biol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.145501_bb0200","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ymthe.2018.12.011","article-title":"Improving mRNA-based therapeutic gene delivery by expression-augmenting 3\u2032 UTRs identified by cellular library screening","volume":"27","author":"von Niessen","year":"2019","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb0205","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1038\/s41467-024-49508-2","article-title":"Optimizing 5\u2019UTRs for mRNA-delivered gene editing using deep learning","volume":"15","author":"Castillo-Hair","year":"2024","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.145501_bb0210","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41587-019-0164-5","article-title":"Human 5\u2019 UTR design and variant effect prediction from a massively parallel translation assay","volume":"37","author":"Sample","year":"2019","journal-title":"Nat. Biotechnol."},{"issue":"22","key":"10.1016\/j.ijbiomac.2025.145501_bb0215","doi-asserted-by":"crossref","first-page":"9053","DOI":"10.1158\/0008-5472.CAN-10-2880","article-title":"Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor","volume":"70","author":"Zhao","year":"2010","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.145501_bb0220","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics--developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.145501_bb0225","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1586\/14760584.2015.973859","article-title":"mRNA transcript therapy","volume":"14","author":"Weissman","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ijbiomac.2025.145501_bb0230","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.virol.2015.01.019","article-title":"Innate immune restriction and antagonism of viral RNA lacking 2\u2032-O methylation","volume":"479-480","author":"Hyde","year":"2015","journal-title":"Virology"},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.145501_bb0235","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1016\/j.molcel.2024.04.011","article-title":"2\u2019-O-methylation at internal sites on mRNA promotes mRNA stability","volume":"84","author":"Li","year":"2024","journal-title":"Mol. Cell"},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.145501_bb0240","first-page":"1486","article-title":"Synthesis and properties of mRNAs containing the novel \u201canti-reverse\u201d cap analogs 7-methyl(3\u2019-O-methyl)GpppG and 7-methyl (3\u2019-deoxy)GpppG","volume":"7","author":"Stepinski","year":"2001","journal-title":"RNA"},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.145501_bb0245","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1261\/rna.5430403","article-title":"Novel \u201canti-reverse\u201d cap analogs with superior translational properties","volume":"9","author":"Jemielity","year":"2003","journal-title":"RNA"},{"key":"10.1016\/j.ijbiomac.2025.145501_bb0255","series-title":"Ability of Nucleoside-modified mRNA to Encode HIV-1 Envelope Trimer Nanoparticles, bioRxiv","author":"Mu","year":"2021"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb0260","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41392-022-00950-y","article-title":"Advances in COVID-19 mRNA vaccine development","volume":"7","author":"Fang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.145501_bb0265","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41587-021-00933-4","article-title":"In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels","volume":"39","author":"Rothgangl","year":"2021","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb0270","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1039\/C6SC02437H","article-title":"A novel route for preparing 5\u2032 cap mimics and capped RNAs: phosphate-modified cap analogues obtained via click chemistry","volume":"8","author":"Walczak","year":"2017","journal-title":"Chem. Sci."},{"issue":"31","key":"10.1016\/j.ijbiomac.2025.145501_bb0275","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1016\/j.tetlet.2017.06.060","article-title":"Synthesis of the first double-functionalized dinucleotide mRNA cap analogue for its specific labeling","volume":"58","author":"Piecyk","year":"2017","journal-title":"Tetrahedron Lett."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.145501_bb0280","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1021\/acs.bioconjchem.0c00080","article-title":"Effect of HIV-1 TAT peptide fusion on 5\u2019 mRNA cap analogs cell membrane permeability and translation inhibition","volume":"31","author":"Piecyk","year":"2020","journal-title":"Bioconjug. Chem."},{"issue":"1762","key":"10.1016\/j.ijbiomac.2025.145501_bb0285","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2018.0167","article-title":"mRNAs biotinylated within the 5\u2032 cap and protected against decapping: new tools to capture RNA-protein complexes","volume":"373","author":"Bednarek","year":"2018","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.145501_bb0290","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.cell.2017.02.019","article-title":"5\u2032 end nicotinamide adenine dinucleotide cap in human cells promotes RNA decay through DXO-mediated deNADding","volume":"168","author":"Jiao","year":"2017","journal-title":"Cell"},{"issue":"23","key":"10.1016\/j.ijbiomac.2025.145501_bb0295","doi-asserted-by":"crossref","first-page":"7650","DOI":"10.1021\/acs.orglett.8b03386","article-title":"Nicotinamide-containing di- and trinucleotides as chemical tools for studies of NAD-capped RNAs","volume":"20","author":"Mlynarska-Cieslak","year":"2018","journal-title":"Org. Lett."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.145501_bb0300","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/nar\/gkaa032","article-title":"The identity and methylation status of the first transcribed nucleotide in eukaryotic mRNA 5\u2032 cap modulates protein expression in living cells","volume":"48","author":"Sikorski","year":"2020","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.145501_bb0305","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1101\/gad.5.11.2108","article-title":"The cap and poly(A) tail function synergistically to regulate mRNA translational efficiency","volume":"5","author":"Gallie","year":"1991","journal-title":"Genes Dev."},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.145501_bb0310","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/nsmb.3499","article-title":"Short poly(A) tails are a conserved feature of highly expressed genes","volume":"24","author":"Lima","year":"2017","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"13","key":"10.1016\/j.ijbiomac.2025.145501_bb0315","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1182\/blood-2006-04-015024","article-title":"Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells","volume":"108","author":"Holtkamp","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.145501_bb0320","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrm2370","article-title":"Multifunctional deadenylase complexes diversify mRNA control","volume":"9","author":"Goldstrohm","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.145501_bb0325","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nsmb.2311","article-title":"Translational control by changes in poly(A) tail length: recycling mRNAs","volume":"19","author":"Weill","year":"2012","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"7494","key":"10.1016\/j.ijbiomac.2025.145501_bb0330","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/nature13007","article-title":"Poly(A)-tail profiling reveals an embryonic switch in translational control","volume":"508","author":"Subtelny","year":"2014","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.145501_bb0335","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.molcel.2016.04.007","article-title":"Regulation of poly(A) tail and translation during the somatic cell cycle","volume":"62","author":"Park","year":"2016","journal-title":"Mol. Cell"},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.145501_bb0340","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.molcel.2014.02.007","article-title":"TAIL-seq: genome-wide determination of poly(A) tail length and 3\u2032 end modifications","volume":"53","author":"Chang","year":"2014","journal-title":"Mol. Cell"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.145501_bb0345","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.tcb.2018.11.002","article-title":"Tales of detailed poly(A) tails","volume":"29","author":"Nicholson","year":"2019","journal-title":"Trends Cell Biol."},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.145501_bb0350","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1261\/rna.077099.120","article-title":"Phosphodiester modifications in mRNA poly(A) tail prevent deadenylation without compromising protein expression","volume":"26","author":"Strzelecka","year":"2020","journal-title":"RNA"},{"key":"10.1016\/j.ijbiomac.2025.145501_bb0355","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41587-024-02174-7","article-title":"Branched chemically modified poly(A) tails enhance the translation capacity of mRNA","volume":"43","author":"Chen","year":"2025","journal-title":"Nat. Biotechnol."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.145501_bb0360","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00833-16","article-title":"RNAs containing modified nucleotides fail to trigger RIG-I conformational changes for innate immune signaling","volume":"7","author":"Durbin","year":"2016","journal-title":"mBio"},{"issue":"17","key":"10.1016\/j.ijbiomac.2025.145501_bb0365","doi-asserted-by":"crossref","first-page":"5884","DOI":"10.1093\/nar\/gkq347","article-title":"Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation","volume":"38","author":"Anderson","year":"2010","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.145501_bb0370","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s10616-022-00540-4","article-title":"N-methylpseudouridine-incorporated mRNA enhances exogenous protein expression and suppresses immunogenicity in primary human fibroblast-like synoviocytes","volume":"74","author":"Mokuda","year":"2022","journal-title":"Cytotechnology"},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.145501_bb0375","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/mt.2015.103","article-title":"Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals","volume":"23","author":"Thess","year":"2015","journal-title":"Mol. Ther."},{"issue":"7893","key":"10.1016\/j.ijbiomac.2025.145501_bb0380","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41586-021-04231-6","article-title":"Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine","volume":"601","author":"Gebre","year":"2022","journal-title":"Nature"},{"issue":"7864","key":"10.1016\/j.ijbiomac.2025.145501_bb0385","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/d41586-021-01661-0","article-title":"CureVac COVID vaccine let-down spotlights mRNA design challenges","volume":"594","author":"Dolgin","year":"2021","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.145501_bb0390","article-title":"Assessment of immunogenicity and efficacy of CV0501 mRNA-based omicron COVID-19 vaccination in small animal models","volume":"11","author":"Roth","year":"2023","journal-title":"Vaccines-Basel"},{"key":"10.1016\/j.ijbiomac.2025.145501_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105494","article-title":"Targeting the alphavirus virus replication process for antiviral development","volume":"210","author":"Tan","year":"2023","journal-title":"Antiviral Res."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb0405","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1038\/s41467-022-31005-z","article-title":"Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infection","volume":"13","author":"Rappaport","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2025.145501_bb0410","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.omtm.2022.03.013","article-title":"Self-amplifying mRNA SARS-CoV-2 vaccines raise cross-reactive immune response to variants and prevent infection in animal models","volume":"25","author":"Palladino","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.ijbiomac.2025.145501_bb0415","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.coviro.2017.11.006","article-title":"Innate immune control of alphavirus infection","volume":"28","author":"Carpentier","year":"2018","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.ijbiomac.2025.145501_bb0420","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1261243","article-title":"Amplifying mRNA vaccines: potential versatile magicians for oncotherapy","volume":"14","author":"Hu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.145501_bb0425","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.omtm.2018.10.010","article-title":"Efficient induction of T cells against conserved HIV-1 regions by mosaic vaccines delivered as self-amplifying mRNA","volume":"12","author":"Moyo","year":"2019","journal-title":"Mol Ther-Meth Clin D"},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.145501_bb0430","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.vaccine.2020.12.070","article-title":"Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: a phase 1 trial","volume":"39","author":"Aldrich","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.ijbiomac.2025.145501_bb0435","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.omtm.2022.09.013","article-title":"Self-amplifying mRNA bicistronic influenza vaccines raise cross-reactive immune responses in mice and prevent infection in ferrets","volume":"27","author":"Chang","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb0440","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ymthe.2019.09.009","article-title":"A trans-amplifying RNA vaccine strategy for induction of potent protective immunity","volume":"28","author":"Beissert","year":"2020","journal-title":"Mol. Ther."},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.145501_bb0445","article-title":"A bivalent trans-amplifying RNA vaccine candidate induces potent Chikungunya and Ross River virus specific immune responses","volume":"10","author":"Schmidt","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ijbiomac.2025.145501_bb0450","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/s41587-024-02306-z","article-title":"Complete substitution with modified nucleotides in self-amplifying RNA suppresses the interferon response and increases potency","volume":"43","author":"Mcgee","year":"2025","journal-title":"Nat. Biotechnol."},{"issue":"43","key":"10.1016\/j.ijbiomac.2025.145501_bb0455","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202402936","article-title":"A novel self-amplifying mRNA with decreased cytotoxicity and enhanced protein expression by macrodomain mutations","volume":"11","author":"Gong","year":"2024","journal-title":"Adv. Sci."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.145501_bb0460","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030733","article-title":"Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types","volume":"7","author":"Salzman","year":"2012","journal-title":"PloS One"},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.145501_bb0465","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1073\/pnas.73.11.3852","article-title":"Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures","volume":"73","author":"Sanger","year":"1976","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb0470","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1038\/s41467-018-05096-6","article-title":"Engineering circular RNA for potent and stable translation in eukaryotic cells","volume":"9","author":"Wesselhoeft","year":"2018","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.145501_bb0475","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.ymthe.2019.07.001","article-title":"Circular RNAs: a novel class of functional RNA molecules with a therapeutic perspective","volume":"27","author":"Santer","year":"2019","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.145501_bb0480","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.molcel.2018.06.034","article-title":"The biogenesis, functions, and challenges of circular RNAs","volume":"71","author":"Li","year":"2018","journal-title":"Mol. Cell"},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.145501_bb0485","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1093\/nar\/19.11.3067","article-title":"The use of BrCN for assembling modified DNA duplexes and DNA-RNA hybrids; comparison with water-soluble carbodiimide","volume":"19","author":"Dolinnaya","year":"1991","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ijbiomac.2025.145501_bb0490","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/978-1-4939-7562-4_15","article-title":"Preparation of circular RNA in vitro","volume":"1724","author":"Abe","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ijbiomac.2025.145501_bb0495","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41551-024-01262-y","article-title":"Expanded toolkits for RNA circularization","volume":"9","author":"Wang","year":"2025","journal-title":"Nat. Biomed. Eng."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.145501_bb0500","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.ymthe.2024.04.028","article-title":"Circular RNA vaccines against monkeypox virus provide potent protection against vaccinia virus infection in mice","volume":"32","author":"Zhou","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ijbiomac.2025.145501_bb0505","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.omtn.2022.09.010","article-title":"Intratumoral delivered novel circular mRNA encoding cytokines for immune modulation and cancer therapy","volume":"30","author":"Yang","year":"2022","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb0510","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-31327-y","article-title":"Pervasive translation of circular RNAs driven by short IRES-like elements","volume":"13","author":"Fan","year":"2022","journal-title":"Nat. Commun."},{"issue":"20","key":"10.1016\/j.ijbiomac.2025.145501_bb0515","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.1016\/j.molcel.2021.07.042","article-title":"Structured elements drive extensive circular RNA translation","volume":"81","author":"Chen","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ijbiomac.2025.145501_bb0520","doi-asserted-by":"crossref","unstructured":"E. Broset, V. Lampaya, A. Larraga, V. Navarro, A. L\u00f3pez, D. de Miguel, \u00c1. Pe\u00f1a, J. Mart\u00ednez-Oliv\u00e1n, D. Casabona, A complete approach for circRNA therapeutics from purification to lyophilized delivery using novel ionizable lipids, bioRxiv (2024) 2024.10.28.620632.","DOI":"10.1101\/2024.10.28.620632"},{"key":"10.1016\/j.ijbiomac.2025.145501_bb0525","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-024-01306-3","article-title":"Efficient circular RNA synthesis for potent rolling circle translation","author":"Du","year":"2024","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.ijbiomac.2025.145501_bb0530","doi-asserted-by":"crossref","unstructured":"Y. Jiang, J. Kjems, RNA denaturation underlies circular RNA separation, bioRxiv (2025) 2025.01.04.631262.","DOI":"10.1101\/2025.01.04.631262"},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.145501_bb0535","doi-asserted-by":"crossref","DOI":"10.3390\/chemosensors12070120","article-title":"Study on the characterization and degradation pattern of circular RNA vaccines using an HPLC method","volume":"12","author":"Cheng","year":"2024","journal-title":"Chemosensors"},{"key":"10.1016\/j.ijbiomac.2025.145501_bb0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.seppur.2025.132809","article-title":"Purifying circular RNA by ultrafiltration","volume":"366","author":"Guillen-Cuevas","year":"2025","journal-title":"Sep. Purif. Technol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb0545","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkae1179","article-title":"CICADA: a circRNA effort toward the ghost proteome","volume":"53","author":"Fan","year":"2025","journal-title":"Nucleic Acids Res."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.145501_bb0550","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1080\/15476286.2019.1600395","article-title":"Circbank: a comprehensive database for circRNA with standard nomenclature","volume":"16","author":"Liu","year":"2019","journal-title":"RNA Biol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb0555","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008040","article-title":"TCCIA: a comprehensive resource for exploring CircRNA in cancer immunotherapy","volume":"12","author":"Wang","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.145501_bb0560","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.cell.2009.01.019","article-title":"The many pathways of RNA degradation","volume":"136","author":"Houseley","year":"2009","journal-title":"Cell"},{"issue":"18","key":"10.1016\/j.ijbiomac.2025.145501_bb0565","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21186582","article-title":"mRNA vaccine era-mechanisms, drug platform and clinical prospection","volume":"21","author":"Xu","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.145501_bb0570","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.3089","article-title":"Transcutaneous delivery of DNA\/mRNA for cancer therapeutic vaccination","volume":"21","author":"Sun","year":"2019","journal-title":"J. Gene Med."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.145501_bb0575","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","article-title":"Delivering the messenger: advances in technologies for therapeutic mRNA delivery","volume":"27","author":"Kowalski","year":"2019","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.145501_bb0580","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/CJI.0b013e3181a00068","article-title":"Direct injection of protamine-protected mRNA: results of a phase 1\/2 vaccination trial in metastatic melanoma patients","volume":"32","author":"Weide","year":"2009","journal-title":"J. Immunother."},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.145501_bb0585","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.4161\/hv.25181","article-title":"A novel, disruptive vaccination technology: self-adjuvanted RNActive((R)) vaccines","volume":"9","author":"Kallen","year":"2013","journal-title":"Hum. Vaccin. Immunother."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb0590","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0b013e3181f7dbe8","article-title":"Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity","volume":"34","author":"Fotin-Mleczek","year":"2011","journal-title":"J. Immunother."},{"issue":"10101","key":"10.1016\/j.ijbiomac.2025.145501_bb0595","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(17)31665-3","article-title":"Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial","volume":"390","author":"Alberer","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.145501_bb0600","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00262-019-02315-x","article-title":"A phase I\/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB\/IV non-small cell lung cancer","volume":"68","author":"Sebastian","year":"2019","journal-title":"Cancer Immunol Immun"},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.145501_bb0605","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1096\/fj.04-2322fje","article-title":"Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: in vitro and in vivo study","volume":"19","author":"Park","year":"2005","journal-title":"FASEB J."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.145501_bb0610","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13060877","article-title":"Protamine-based strategies for RNA transfection","volume":"13","author":"Jarzebska","year":"2021","journal-title":"Pharmaceutics"},{"issue":"5867","key":"10.1016\/j.ijbiomac.2025.145501_bb0615","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1126\/science.1153124","article-title":"Ceramide triggers budding of exosome vesicles into multivesicular endosomes","volume":"319","author":"Trajkovic","year":"2008","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.145501_bb0620","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1016\/j.matt.2022.06.012","article-title":"Inhalable dry powder mRNA vaccines based on extracellular vesicles","volume":"5","author":"Popowski","year":"2022","journal-title":"Matter"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.145501_bb0625","doi-asserted-by":"crossref","first-page":"630","DOI":"10.55730\/1300-0144.5625","article-title":"Exosome-mediated long noncoding RNA (lncRNA) PART1 suppresses malignant progression of oral squamous cell carcinoma via miR-17-5p\/SOCS6 axis","volume":"53","author":"Du","year":"2023","journal-title":"Turk J Med Sci"},{"key":"10.1016\/j.ijbiomac.2025.145501_bb0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.archoralbio.2023.105753","article-title":"Exosome-mediated small interfering RNA delivery inhibits aberrant osteoblast differentiation in Apert syndrome model mice","volume":"153","author":"Myo","year":"2023","journal-title":"Arch. Oral Biol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb0635","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/mt.2012.180","article-title":"Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells","volume":"21","author":"Ohno","year":"2013","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb0640","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1186\/s12951-024-02634-x","article-title":"Exosome for mRNA delivery: strategies and therapeutic applications","volume":"22","author":"Iqbal","year":"2024","journal-title":"J Nanobiotechnology"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb0645","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41551-019-0485-1","article-title":"Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation","volume":"4","author":"Yang","year":"2020","journal-title":"Nat. Biomed. Eng."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb0650","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1158\/1541-7786.MCR-16-0191","article-title":"Exosomes promote ovarian cancer cell invasion through transfer of CD44 to peritoneal mesothelial cells","volume":"15","author":"Nakamura","year":"2017","journal-title":"Mol. Cancer Res."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.145501_bb0655","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.4049\/jimmunol.161.3.1313","article-title":"Dendritic cells interact directly with naive B lymphocytes to transfer antigen and initiate class switching in a primary T-dependent response","volume":"161","author":"Wykes","year":"1998","journal-title":"J. Immunol."},{"issue":"14","key":"10.1016\/j.ijbiomac.2025.145501_bb0660","doi-asserted-by":"crossref","first-page":"7715","DOI":"10.1039\/C4NR01346H","article-title":"Messenger RNA (mRNA) nanoparticle tumour vaccination","volume":"6","author":"Phua","year":"2014","journal-title":"Nanoscale"},{"key":"10.1016\/j.ijbiomac.2025.145501_bb0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102405","article-title":"The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines","volume":"107","author":"Wei","year":"2022","journal-title":"Cancer Treat. Rev."},{"issue":"1\u20132","key":"10.1016\/j.ijbiomac.2025.145501_bb0670","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ijpharm.2017.10.030","article-title":"Cationic nanoemulsions as nucleic acids delivery systems","volume":"534","author":"Teixeira","year":"2017","journal-title":"Int. J. Pharm."},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.145501_bb0675","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1038\/mt.2014.133","article-title":"A cationic nanoemulsion for the delivery of next-generation RNA vaccines","volume":"22","author":"Brito","year":"2014","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.145501_bb0680","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/infdis\/jiu522","article-title":"Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion","volume":"211","author":"Bogers","year":"2015","journal-title":"J Infect Dis"},{"issue":"555","key":"10.1016\/j.ijbiomac.2025.145501_bb0685","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc9396","article-title":"An alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates","volume":"12","author":"Erasmus","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ijbiomac.2025.145501_bb0690","series-title":"Single-dose Replicating RNA Vaccine Induces Neutralizing Antibodies Against SARS-CoV-2 in Nonhuman Primates, bioRxiv","author":"Erasmus","year":"2020"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.145501_bb0695","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.xphs.2020.12.006","article-title":"Addressing the cold reality of mRNA vaccine stability","volume":"110","author":"Crommelin","year":"2021","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.145501_bb0700","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ymthe.2004.12.006","article-title":"Formation and intracellular trafficking of lipoplexes and polyplexes","volume":"11","author":"Elouahabi","year":"2005","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.145501_bb0705","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0005-2736(98)00199-0","article-title":"Interactions of polymeric and liposomal gene delivery systems with extracellular glycosaminoglycans: physicochemical and transfection studies","volume":"1415","author":"Ruponen","year":"1999","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb0710","doi-asserted-by":"crossref","DOI":"10.1186\/s12951-021-00994-2","article-title":"The impact of anionic polymers on gene delivery: how composition and assembly help evading the toxicity-efficiency dilemma","volume":"19","author":"Richter","year":"2021","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.ijbiomac.2025.145501_bb0715","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120362","article-title":"Recent advances in peptide-targeted micelleplexes: current developments and future perspectives","volume":"597","author":"Costa","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.145501_bb0720","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jconrel.2010.07.124","article-title":"mRNA transfection of cervical carcinoma and mesenchymal stem cells mediated by cationic carriers","volume":"147","author":"Rejman","year":"2010","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb0725","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jconrel.2006.04.014","article-title":"Toxicity of cationic lipids and cationic polymers in gene delivery","volume":"114","author":"Lv","year":"2006","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb0730","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jconrel.2004.11.008","article-title":"Polyethylenimine with acid-labile linkages as a biodegradable gene carrier","volume":"103","author":"Kim","year":"2005","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb0735","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s13346-020-00790-9","article-title":"PEI fluorination reduces toxicity and promotes liver-targeted siRNA delivery","volume":"11","author":"Xue","year":"2021","journal-title":"Drug Deliv. Transl. Res."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.145501_bb0740","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.3109\/10717544.2015.1038856","article-title":"Induction of HIV-1 gag specific immune responses by cationic micelles mediated delivery of gag mRNA","volume":"23","author":"Zhao","year":"2016","journal-title":"Drug Deliv."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.145501_bb0745","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/sj.mt.6300132","article-title":"Rapid optimization of gene delivery by parallel end-modification of poly(beta-amino ester)s","volume":"15","author":"Zugates","year":"2007","journal-title":"Mol. Ther."},{"issue":"44","key":"10.1016\/j.ijbiomac.2025.145501_bb0750","doi-asserted-by":"crossref","first-page":"13808","DOI":"10.1002\/anie.201608450","article-title":"Polymer-lipid nanoparticles for systemic delivery of mRNA to the lungs","volume":"55","author":"Kaczmarek","year":"2016","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"14","key":"10.1016\/j.ijbiomac.2025.145501_bb0755","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201800249","article-title":"Poly(beta-amino ester)-co-poly(caprolactone) terpolymers as nonviral vectors for mRNA delivery in vitro and in vivo","volume":"7","author":"Capasso Palmiero","year":"2018","journal-title":"Adv. Healthc. Mater."},{"issue":"17","key":"10.1016\/j.ijbiomac.2025.145501_bb0760","article-title":"mRNA delivery system for targeting antigen-presenting cells in vivo","volume":"7","author":"Fornaguera","year":"2018","journal-title":"Adv. Healthc. Mater."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.145501_bb0765","doi-asserted-by":"crossref","first-page":"E448","DOI":"10.1073\/pnas.1614193114","article-title":"Charge-altering releasable transporters (CARTs) for the delivery and release of mRNA in living animals","volume":"114","author":"McKinlay","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"26","key":"10.1016\/j.ijbiomac.2025.145501_bb0770","doi-asserted-by":"crossref","first-page":"E5859","DOI":"10.1073\/pnas.1805358115","article-title":"Enhanced mRNA delivery into lymphocytes enabled by lipid-varied libraries of charge-altering releasable transporters","volume":"115","author":"McKinlay","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"39","key":"10.1016\/j.ijbiomac.2025.145501_bb0775","doi-asserted-by":"crossref","first-page":"E9153","DOI":"10.1073\/pnas.1810002115","article-title":"mRNA vaccination with charge-altering releasable transporters elicits human T cell responses and cures established tumors in mice","volume":"115","author":"Haabeth","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"33","key":"10.1016\/j.ijbiomac.2025.145501_bb0780","doi-asserted-by":"crossref","first-page":"9591","DOI":"10.1002\/anie.201603648","article-title":"A single methylene group in oligoalkylamine-based cationic polymers and lipids promotes enhanced mRNA delivery","volume":"55","author":"Jarzebinska","year":"2016","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.145501_bb0785","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1021\/acs.nanolett.9b04426","article-title":"Quantitating endosomal escape of a library of polymers for mRNA delivery","volume":"20","author":"Jiang","year":"2020","journal-title":"Nano Lett."},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.145501_bb0790","article-title":"Facile synthesis of multifunctional bioreducible polymers for mRNA delivery","volume":"29","author":"Hickey","year":"2023","journal-title":"Chemistry"},{"issue":"15","key":"10.1016\/j.ijbiomac.2025.145501_bb0795","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202202688","article-title":"Polymer-based mRNA delivery strategies for advanced therapies","volume":"12","author":"Yang","year":"2023","journal-title":"Adv. Healthc. Mater."},{"issue":"21","key":"10.1016\/j.ijbiomac.2025.145501_bb0800","doi-asserted-by":"crossref","first-page":"7413","DOI":"10.1073\/pnas.84.21.7413","article-title":"Lipofection - a highly efficient, lipid-mediated DNA-transfection procedure","volume":"84","author":"Felgner","year":"1987","journal-title":"P Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb0805","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s42003-024-06235-0","article-title":"Overcoming thermostability challenges in mRNA-lipid nanoparticle systems with piperidine-based ionizable lipids","volume":"7","author":"Hashiba","year":"2024","journal-title":"Commun Biol"},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.145501_bb0810","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abf4398","article-title":"Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver","volume":"7","author":"Kim","year":"2021","journal-title":"Sci. Adv."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.145501_bb0815","article-title":"Cationic liposomes carrying siRNA: impact of lipid composition on physicochemical properties, cytotoxicity and endosomal escape","volume":"8","author":"Lechanteur","year":"2018","journal-title":"Nanomaterials-Basel"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.145501_bb0820","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15041184","article-title":"Key design features of lipid nanoparticles and electrostatic charge-based lipid nanoparticle targeting","volume":"15","author":"Gyanani","year":"2023","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.145501_bb0825","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.tips.2021.03.002","article-title":"The importance of apparent pKa in the development of nanoparticles encapsulating siRNA and mRNA","volume":"42","author":"Patel","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ijbiomac.2025.145501_bb0830","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115446","article-title":"Breaking the final barrier: evolution of cationic and ionizable lipid structure in lipid nanoparticles to escape the endosome","volume":"214","author":"Mrksich","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.145501_bb0835","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1021\/acs.molpharmaceut.2c00033","article-title":"Comparison of DLin-MC3-DMA and ALC-0315 for siRNA delivery to hepatocytes and hepatic stellate cells","volume":"19","author":"Ferraresso","year":"2022","journal-title":"Mol. Pharm."},{"issue":"Pt A","key":"10.1016\/j.ijbiomac.2025.145501_bb0840","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.addr.2016.01.022","article-title":"The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery","volume":"99","author":"Cheng","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.145501_bb0845","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/10717544.2017.1388451","article-title":"Cleavable PEGylation: a strategy for overcoming the \u201cPEG dilemma\u201d in efficient drug delivery","volume":"24","author":"Fang","year":"2017","journal-title":"Drug Deliv."},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.145501_bb0850","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1039\/D1CS00617G","article-title":"Emerging mRNA technologies: delivery strategies and biomedical applications","volume":"51","author":"Xiao","year":"2022","journal-title":"Chem. Soc. Rev."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb0855","article-title":"Nanomaterial delivery systems for mRNA vaccines","volume":"9","author":"Buschmann","year":"2021","journal-title":"Vaccines-Basel"},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.145501_bb0860","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ymthe.2004.12.018","article-title":"Nonbilayer phase of lipoplex-membrane mixture determines endosomal escape of genetic cargo and transfection efficiency","volume":"11","author":"Zuhorn","year":"2005","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb0865","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1038\/s41598-024-52685-1","article-title":"A careful look at lipid nanoparticle characterization: analysis of benchmark formulations for encapsulation of RNA cargo size gradient","volume":"14","author":"Schober","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb0870","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/acs.accounts.1c00544","article-title":"Chemistry of lipid nanoparticles for RNA delivery","volume":"55","author":"Eygeris","year":"2022","journal-title":"Acc. Chem. Res."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.145501_bb0875","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.nantod.2014.04.008","article-title":"Challenges associated with penetration of nanoparticles across cell and tissue barriers: a review of current status and future prospects","volume":"9","author":"Barua","year":"2014","journal-title":"Nano Today"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.145501_bb0880","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1021\/acs.molpharmaceut.9b01182","article-title":"The effect of size and charge of lipid nanoparticles prepared by microfluidic mixing on their lymph node transitivity and distribution","volume":"17","author":"Nakamura","year":"2020","journal-title":"Mol. Pharm."},{"issue":"35","key":"10.1016\/j.ijbiomac.2025.145501_bb0885","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2400194121","article-title":"Supramolecular assembly of polycation\/mRNA nanoparticles and in vivo monocyte programming","volume":"121","author":"Hu","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijbiomac.2025.145501_bb0890","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/s41551-023-01030-4","article-title":"Peptide-encoding mRNA barcodes for the high-throughput in vivo screening of libraries of lipid nanoparticles for mRNA delivery","volume":"7","author":"Rhym","year":"2023","journal-title":"Nat. Biomed. Eng."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.145501_bb0895","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/0300985817738095","article-title":"Safety evaluation of lipid nanoparticle-formulated modified mRNA in the Sprague-Dawley rat and Cynomolgus monkey","volume":"55","author":"Sedic","year":"2018","journal-title":"Vet. Pathol."},{"key":"10.1016\/j.ijbiomac.2025.145501_bb0900","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jconrel.2020.03.006","article-title":"Different kinetics for the hepatic uptake of lipid nanoparticles between the apolipoprotein E\/low density lipoprotein receptor and the N-acetyl-d-galactosamine\/asialoglycoprotein receptor pathway","volume":"322","author":"Sato","year":"2020","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb0905","doi-asserted-by":"crossref","first-page":"5659","DOI":"10.1038\/s41467-024-50093-7","article-title":"Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation","volume":"15","author":"Su","year":"2024","journal-title":"Nat. Commun."},{"issue":"33","key":"10.1016\/j.ijbiomac.2025.145501_bb0910","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201902575","article-title":"Fast and efficient CRISPR\/Cas9 genome editing in vivo enabled by bioreducible lipid and messenger RNA nanoparticles","volume":"31","author":"Liu","year":"2019","journal-title":"Adv. Mater."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.145501_bb0915","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"issue":"22","key":"10.1016\/j.ijbiomac.2025.145501_bb0920","doi-asserted-by":"crossref","first-page":"15085","DOI":"10.1021\/jacs.4c00451","article-title":"Multicomponent synthesis of imidazole-based Ionizable lipids for highly efficient and spleen-selective messenger RNA delivery","volume":"146","author":"Dong","year":"2024","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ijbiomac.2025.145501_bb0925","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41565-024-01747-6","article-title":"Combinatorial design of siloxane-incorporated lipid nanoparticles augments intracellular processing for tissue-specific mRNA therapeutic delivery","volume":"20","author":"Xue","year":"2025","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ijbiomac.2025.145501_bb0930","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jconrel.2024.10.028","article-title":"Paracyclophane-based ionizable lipids for efficient mRNA delivery in vivo","volume":"376","author":"Wu","year":"2024","journal-title":"J. Control. Release"},{"issue":"48","key":"10.1016\/j.ijbiomac.2025.145501_bb0935","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202409812","article-title":"Simplified lipid nanoparticles for tissue- and cell-targeted mRNA delivery facilitate precision tumor therapy in a lung metastasis mouse model","volume":"36","author":"Fei","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ijbiomac.2025.145501_bb0940","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jconrel.2019.10.001","article-title":"Leukocyte-specific siRNA delivery revealing IRF8 as a potential anti-inflammatory target","volume":"313","author":"Veiga","year":"2019","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.145501_bb0945","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41565-017-0043-5","article-title":"A modular platform for targeted RNAi therapeutics","volume":"13","author":"Kedmi","year":"2018","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ijbiomac.2025.145501_bb0950","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1038\/s41565-024-01765-4","article-title":"Acid-degradable lipid nanoparticles enhance the delivery of mRNA","volume":"19","author":"Zhao","year":"2024","journal-title":"Nat. Nanotechnol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb0955","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s12951-022-01478-7","article-title":"Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects","volume":"20","author":"Kiaie","year":"2022","journal-title":"J Nanobiotechnology"},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.145501_bb0960","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1208\/s12249-024-02850-6","article-title":"Lipoplexes\u2019 structure, preparation, and role in managing different diseases","volume":"25","author":"El-Zahaby","year":"2024","journal-title":"AAPS PharmSciTech"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.145501_bb0965","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41590-022-01160-y","article-title":"IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines","volume":"23","author":"Tahtinen","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.145501_bb0970","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jconrel.2024.04.052","article-title":"Alpha-galactosylceramide improves the potency of mRNA LNP vaccines against cancer and intracellular bacteria","volume":"370","author":"Meulewaeter","year":"2024","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.145501_bb0975","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101260","article-title":"Development of novel lipoplex formulation methodologies to improve large-scale transient transfection for lentiviral vector manufacture","volume":"32","author":"Williams-Fegredo","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"7607","key":"10.1016\/j.ijbiomac.2025.145501_bb0980","doi-asserted-by":"crossref","first-page":"396-+","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.145501_bb0985","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1007\/s00262-021-03134-9","article-title":"Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16(+) cancer","volume":"71","author":"Salomon","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"issue":"7963","key":"10.1016\/j.ijbiomac.2025.145501_bb0990","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2025.145501_bb0995","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.biomaterials.2017.02.019","article-title":"Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination","volume":"125","author":"Persano","year":"2017","journal-title":"Biomaterials"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.145501_bb1000","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1012116","article-title":"Broad-spectrum Delta-BA.2 tandem-fused heterodimer mRNA vaccine delivered by lipopolyplex","volume":"20","author":"Du","year":"2024","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ijbiomac.2025.145501_bb1005","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jconrel.2024.01.002","article-title":"An inoculation site-retained mRNA vaccine induces robust immune responses against SARS-CoV-2 variants","volume":"366","author":"Huang","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2025.145501_bb1010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104586","article-title":"Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SW-BIC-213, as a heterologous booster in healthy adults: an open-labeled, two-centered and multi-arm randomised, phase 1 trial","volume":"91","author":"Gui","year":"2023","journal-title":"EBioMedicine"},{"issue":"41","key":"10.1016\/j.ijbiomac.2025.145501_bb1015","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adn9961","article-title":"Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity","volume":"10","author":"Fan","year":"2024","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb1020","article-title":"Recent progress on the versatility of virus-like particles","volume":"8","author":"Qian","year":"2020","journal-title":"Vaccines (Basel)"},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.145501_bb1025","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41587-020-00781-8","article-title":"Targeting herpes simplex virus with CRISPR-Cas9 cures herpetic stromal keratitis in mice","volume":"39","author":"Yin","year":"2021","journal-title":"Nat. Biotechnol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.145501_bb1030","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41551-020-00656-y","article-title":"Lentiviral delivery of co-packaged Cas9 mRNA and a Vegfa-targeting guide RNA prevents wet age-related macular degeneration in mice","volume":"5","author":"Ling","year":"2021","journal-title":"Nat Biomed Eng"},{"issue":"6557","key":"10.1016\/j.ijbiomac.2025.145501_bb1035","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1126\/science.abg6155","article-title":"Mammalian retrovirus-like protein PEG10 packages its own mRNA and can be pseudotyped for mRNA delivery","volume":"373","author":"Segel","year":"2021","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.145501_bb1040","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1038\/s41587-021-01124-x","article-title":"RNA delivery with a human virus-like particle","volume":"39","author":"Gutkin","year":"2021","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb1045","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.chembiol.2023.09.015","article-title":"Highly efficient cellular expression of circular mRNA enables prolonged protein expression","volume":"31","author":"Unti","year":"2024","journal-title":"Cell Chem. Biol."},{"issue":"13","key":"10.1016\/j.ijbiomac.2025.145501_bb1050","doi-asserted-by":"crossref","first-page":"12542","DOI":"10.1074\/jbc.M310175200","article-title":"mRNA is an endogenous ligand for toll-like receptor 3","volume":"279","author":"Karik\u00f3","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.145501_bb1055","doi-asserted-by":"crossref","first-page":"7204","DOI":"10.18632\/oncotarget.23208","article-title":"Inflammatory responses and inflammation-associated diseases in organs","volume":"9","author":"Chen","year":"2018","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.145501_bb1060","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103479","article-title":"The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory","volume":"24","author":"Ndeupen","year":"2021","journal-title":"Iscience"},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.145501_bb1065","article-title":"Exploring the impact of mRNA modifications on translation efficiency and immune tolerance to self-antigens","volume":"12","author":"Sioud","year":"2024","journal-title":"Vaccines-Basel"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb1070","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.molcel.2019.07.016","article-title":"6-Methyladenosine modification controls circular RNA immunity","volume":"76","author":"Chen","year":"2019","journal-title":"Mol. Cell"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.145501_bb1075","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-025-01344-5","article-title":"Small circular RNAs as vaccines for cancer immunotherapy","volume":"9","author":"Zhang","year":"2025","journal-title":"Nature Biomedical Engineering"},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.145501_bb1080","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.immuni.2022.05.007","article-title":"Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses (vol 54, pg 2877, 2021)","volume":"55","author":"Alameh","year":"2022","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.145501_bb1085","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41590-022-01160-y","article-title":"IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines","volume":"23","author":"Tahtinen","year":"2022","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb1090","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1038\/ncomms2608","article-title":"TRPM2 links oxidative stress to NLRP3 inflammasome activation","volume":"4","author":"Zhong","year":"2013","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb1095","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41541-025-01124-x","article-title":"Ionizable lipid nanoparticles of mRNA vaccines elicit NF-\u03baB and IRF responses through toll-like receptor 4","volume":"10","author":"Zelkoski","year":"2025","journal-title":"npj Vaccines"},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.145501_bb1100","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14102234","article-title":"Cationic polyethyleneimine (PEI)-gold nanocomposites modulate macrophage activation and reprogram mouse breast triple-negative MET-1 tumor immunological microenvironment","volume":"14","author":"Mulens-Arias","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijbiomac.2025.145501_bb1105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.827256","article-title":"TLR7 signaling shapes and maintains antibody diversity upon virus-like particle immunization","volume":"12","author":"Chang","year":"2022","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.145501_bb1110","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1073\/pnas.73.10.3671","article-title":"Molecular determinants of immunogenicity: the immunon model of immune response","volume":"73","author":"Dintzis","year":"1976","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijbiomac.2025.145501_bb1115","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01831","article-title":"Virus-specific secondary plasma cells produce elevated levels of high-avidity antibodies but are functionally short lived","volume":"10","author":"Krueger","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.145501_bb1120","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbpa.2022.102172","article-title":"Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics","volume":"70","author":"Kaur","year":"2022","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb1125","article-title":"Incorporation of a toll-like receptor 2\/6 agonist potentiates mRNA vaccines against cancer and infectious diseases","volume":"8","author":"Gu","year":"2023","journal-title":"Signal Transduct Tar"},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.145501_bb1130","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/s41565-023-01404-4","article-title":"Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines","volume":"18","author":"Han","year":"2023","journal-title":"Nat. Nanotechnol."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.145501_bb1135","doi-asserted-by":"crossref","first-page":"6758","DOI":"10.1021\/acsnano.4c10202","article-title":"A pH-responsive and guanidinium-rich nanoadjuvant efficiently delivers STING agonist for cancer immunotherapy","volume":"19","author":"Lu","year":"2025","journal-title":"ACS Nano"},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.145501_bb1140","doi-asserted-by":"crossref","DOI":"10.1093\/nsr\/nwad214","article-title":"STING agonist-boosted mRNA immunization via intelligent design of nanovaccines for enhancing cancer immunotherapy","volume":"10","author":"Zhou","year":"2023","journal-title":"Natl. Sci. Rev."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb1145","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1038\/s41467-025-58641-5","article-title":"Distinct oligomeric assemblies of STING induced by non-nucleotide agonists","volume":"16","author":"Gharpure","year":"2025","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.145501_bb1150","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1007\/s00262-020-02618-4","article-title":"A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III\/IV melanoma patients who are disease-free following the resection of macrometastases","volume":"69","author":"Jansen","year":"2020","journal-title":"Cancer Immunol Immun"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.145501_bb1155","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/cmi.2017.105","article-title":"Revisiting GM-CSF as an adjuvant for therapeutic vaccines","volume":"15","author":"Zhao","year":"2018","journal-title":"Cell. Mol. Immunol."},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.145501_bb1160","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ccell.2024.07.010","article-title":"Long-lasting mRNA-encoded interleukin-2 restores CD8 T cell neoantigen immunity in MHC class I-deficient cancers (vol 42, pg 568, 2024)","volume":"42","author":"Beck","year":"2024","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.145501_bb1165","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2024.08.017","article-title":"Conversion of vaccines from low to high immunogenicity by antibodies with epitope complementarity","volume":"57","author":"Dvorscek","year":"2024","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.145501_bb1170","article-title":"An mRNA-based broad-spectrum vaccine candidate confers cross-protection against heterosubtypic influenza A viruses","volume":"12","author":"Xiong","year":"2023","journal-title":"Emerg Microbes Infec"},{"issue":"686","key":"10.1016\/j.ijbiomac.2025.145501_bb1175","article-title":"Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice","volume":"15","author":"da Silva","year":"2023","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.145501_bb1180","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1093\/nar\/gkt1321","article-title":"Inhibition of translation by IFIT family members is determined by their ability to interact selectively with the 5\u2032-terminal regions of cap0-, cap1- and 5\u2019ppp- mRNAs","volume":"42","author":"Kumar","year":"2014","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.145501_bb1185","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s41580-021-00430-1","article-title":"Cellular origins of dsRNA, their recognition and consequences","volume":"23","author":"Chen","year":"2022","journal-title":"Nat Rev Mol Cell Bio"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.145501_bb1190","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.it.2007.02.002","article-title":"RIG-I: tri-ing to discriminate between self and non-self RNA","volume":"28","author":"Bowie","year":"2007","journal-title":"Trends Immunol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.145501_bb1195","article-title":"RNA modifications modulate activation of innate toll-like receptors","volume":"10","author":"Freund","year":"2019","journal-title":"Genes-Basel"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb1200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000926","article-title":"RIG-I, MDA5 and TLR3 synergistically play an important role in restriction of dengue virus infection","volume":"5","author":"Nasirudeen","year":"2011","journal-title":"Plos Neglect Trop D"},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.145501_bb1205","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103479","article-title":"The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory","volume":"24","author":"Ndeupen","year":"2021","journal-title":"iScience"},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.145501_bb1210","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1021\/acs.molpharmaceut.2c00033","article-title":"Comparison of DLin-MC3-DMA and ALC-0315 for siRNA delivery to hepatocytes and hepatic stellate cells","volume":"19","author":"Ferraresso","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijbiomac.2025.145501_bb1215","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jconrel.2017.09.044","article-title":"Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus","volume":"266","author":"Sato","year":"2017","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb1220","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.celrep.2013.08.032","article-title":"The peroxisomal enzyme L-PBE is required to prevent the dietary toxicity of medium-chain fatty acids","volume":"5","author":"Ding","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.ijbiomac.2025.145501_bb1225","first-page":"71","article-title":"Formulation and delivery technologies for mRNA vaccines","volume":"440","author":"Zeng","year":"2022","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.145501_bb1230","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","article-title":"Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes","volume":"217","author":"Pardi","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2025.145501_bb1235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2017.06.006","article-title":"Non-human primates as a model for understanding the mechanism of action of toll-like receptor-based vaccine adjuvants","volume":"47","author":"Thompson","year":"2017","journal-title":"Curr. Opin. Immunol."},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.145501_bb1240","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1016\/j.celrep.2020.02.111","article-title":"Route of vaccine administration alters antigen trafficking but not innate or adaptive immunity","volume":"30","author":"Ols","year":"2020","journal-title":"Cell Rep."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.145501_bb1245","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41551-019-0399-y","article-title":"Imaging the early fate of mRNA vaccines","volume":"3","author":"Ols","year":"2019","journal-title":"Nat. Biomed. Eng."},{"issue":"21","key":"10.1016\/j.ijbiomac.2025.145501_bb1250","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1001\/jama.1997.03540450065037","article-title":"Determination of deltoid fat pad thickness. Implications for needle length in adult immunization","volume":"277","author":"Poland","year":"1997","journal-title":"JAMA"},{"issue":"3 Pt 1","key":"10.1016\/j.ijbiomac.2025.145501_bb1255","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1542\/peds.100.3.400","article-title":"Needle length and injection technique for efficient intramuscular vaccine delivery in infants and children evaluated through an ultrasonographic determination of subcutaneous and muscle layer thickness","volume":"100","author":"Groswasser","year":"1997","journal-title":"Pediatrics"},{"issue":"37","key":"10.1016\/j.ijbiomac.2025.145501_bb1260","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.1016\/j.vaccine.2021.06.081","article-title":"Inadequate deltoid muscle penetration and concerns of improper COVID mRNA vaccine administration can be avoided by injection technique modification","volume":"39","author":"Rahamimov","year":"2021","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.145501_bb1265","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0264-410X(89)90157-6","article-title":"Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination","volume":"7","author":"Shaw","year":"1989","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.145501_bb1270","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1080\/21645515.2020.1814094","article-title":"Subcutaneous vaccine administration - an outmoded practice","volume":"17","author":"Cook","year":"2021","journal-title":"Hum. Vaccin. Immunother."},{"issue":"7607","key":"10.1016\/j.ijbiomac.2025.145501_bb1275","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2025.145501_bb1280","series-title":"Subunit Vaccine Delivery","first-page":"261","article-title":"Parenteral vaccine administration: tried and true","author":"Johansen","year":"2015"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.145501_bb1285","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-246485","article-title":"Third cranial nerve palsy in an 88-year-old man after SARS-CoV-2 mRNA vaccination: change of injection site and type of vaccine resulted in an uneventful second dose with humoral immune response","volume":"15","author":"Cicalese","year":"2022","journal-title":"BMJ Case Rep."},{"issue":"24","key":"10.1016\/j.ijbiomac.2025.145501_bb1290","doi-asserted-by":"crossref","DOI":"10.3390\/molecules29245978","article-title":"A review of the role of structural features and environmental conditions","volume":"29","author":"Kornienko","year":"2024","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb1295","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s41467-022-28776-w","article-title":"Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics","volume":"13","author":"Leppek","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb1300","doi-asserted-by":"crossref","first-page":"6777","DOI":"10.1038\/s41467-021-26926-0","article-title":"A novel mechanism for the loss of mRNA activity in lipid nanoparticle delivery systems","volume":"12","author":"Packer","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2025.145501_bb1305","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120586","article-title":"mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability","volume":"601","author":"Schoenmaker","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb1310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13273-021-00171-4","article-title":"Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency","volume":"18","author":"Kim","year":"2022","journal-title":"Mol. Cell. Toxicol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.145501_bb1315","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.xphs.2022.11.001","article-title":"The storage and in-use stability of mRNA vaccines and therapeutics: not a cold case","volume":"112","author":"Oude Blenke","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijbiomac.2025.145501_bb1320","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.omtm.2022.03.009","article-title":"A flexible, thermostable nanostructured lipid carrier platform for RNA vaccine delivery","volume":"25","author":"Gerhardt","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.ijbiomac.2025.145501_bb1325","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2147\/IJN.S123062","article-title":"Achieving long-term stability of lipid nanoparticles: examining the effect of pH, temperature, and lyophilization","volume":"12","author":"Ball","year":"2017","journal-title":"Int. J. Nanomedicine"},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.145501_bb1330","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2144\/000112593","article-title":"Long-term storage of DNA-free RNA for use in vaccine studies","volume":"43","author":"Jones","year":"2007","journal-title":"Biotechniques"},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.145501_bb1335","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1007\/s10311-021-01256-1","article-title":"Advanced packaging for distribution and storage of COVID-19 vaccines: a review","volume":"19","author":"Ramakanth","year":"2021","journal-title":"Environ. Chem. Lett."},{"key":"10.1016\/j.ijbiomac.2025.145501_bb1340","article-title":"mRNA vaccines: the dawn of a new era of cancer immunotherapy","volume":"13","author":"Deng","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb1345","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ijbiomac.2025.145501_bb1350","author":"Mauro"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.145501_bb1360","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7873","key":"10.1016\/j.ijbiomac.2025.145501_bb1365","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s41586-021-03828-1","article-title":"Highly accurate protein structure prediction for the human proteome","volume":"596","author":"Tunyasuvunakool","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2025.145501_bb1370","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/7205241","article-title":"Artificial intelligence-based data-driven strategy to accelerate research, development, and clinical trials of COVID vaccine","volume":"2022","author":"Sharma","year":"2022","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.ijbiomac.2025.145501_bb1375","article-title":"Computational biology and artificial intelligence in mRNA vaccine design for cancer immunotherapy","volume":"14","author":"Imani","year":"2025","journal-title":"Front Cell Infect Mi"},{"issue":"W1","key":"10.1016\/j.ijbiomac.2025.145501_bb1380","doi-asserted-by":"crossref","first-page":"W671","DOI":"10.1093\/nar\/gkab279","article-title":"Vaxign2: the second generation of the first web-based vaccine design program using reverse vaccinology and machine learning","volume":"49","author":"Ong","year":"2021","journal-title":"Nucleic Acids Res."},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.145501_bb1385","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/s42256-022-00571-8","article-title":"Deep learning models for predicting RNA degradation via dual crowdsourcing","volume":"4","author":"Wayment-Steele","year":"2022","journal-title":"Nat Mach Intell"},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.145501_bb1390","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41587-023-01679-x","article-title":"Combinatorial design of nanoparticles for pulmonary mRNA delivery and genome editing","volume":"41","author":"Li","year":"2023","journal-title":"Nat. Biotechnol."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.145501_bb1395","doi-asserted-by":"crossref","DOI":"10.1038\/s41563-024-01867-3","article-title":"Accelerating ionizable lipid discovery for mRNA delivery using machine learning and combinatorial chemistry","volume":"23","author":"Li","year":"2024","journal-title":"Nat. Mater."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb1400","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1038\/s41467-024-50619-z","article-title":"AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery","volume":"15","author":"Xu","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb1405","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-55072-6","article-title":"Artificial intelligence-driven rational design of ionizable lipids for mRNA delivery","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2025.145501_bb1410","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jconrel.2021.03.043","article-title":"The dawn of mRNA vaccines: the COVID-19 case","volume":"333","author":"Verbeke","year":"2021","journal-title":"J. Control. Release"},{"issue":"7893","key":"10.1016\/j.ijbiomac.2025.145501_bb1425","doi-asserted-by":"crossref","first-page":"410-+","DOI":"10.1038\/s41586-021-04231-6","article-title":"Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine","volume":"601","author":"Gebre","year":"2022","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.145501_bb1430","article-title":"Detailed dissection and critical evaluation of the Pfizer\/BioNTech and Moderna mRNA vaccines","volume":"9","author":"Xia","year":"2021","journal-title":"Vaccines-Basel"},{"issue":"7978","key":"10.1016\/j.ijbiomac.2025.145501_bb1435","doi-asserted-by":"crossref","first-page":"396-+","DOI":"10.1038\/s41586-023-06127-z","article-title":"Algorithm for optimized mRNA design improves stability and immunogenicity","volume":"621","author":"Zhang","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2025.145501_bb1440","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120586","article-title":"mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability","volume":"601","author":"Schoenmaker","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijbiomac.2025.145501_bb1445","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.copbio.2021.09.016","article-title":"Principles for designing an optimal mRNA lipid nanoparticle vaccine","volume":"73","author":"Kon","year":"2022","journal-title":"Curr Opin Biotech"},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.145501_bb1450","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1007\/s43440-022-00429-1","article-title":"Efficacy of COVID-19 vaccines: a systematic review and network meta-analysis of phase 3 randomized controlled trials","volume":"74","author":"Kumar","year":"2022","journal-title":"Pharmacol. Rep."},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.145501_bb1455","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: principles, delivery and clinical translation (Aug, 10.1038\/s41573-021-00283-5, 2021)","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"15","key":"10.1016\/j.ijbiomac.2025.145501_bb1460","article-title":"Unsaturated, trialkyl ionizable lipids are versatile lipid-nanoparticle components for therapeutic and vaccine applications","volume":"35","author":"Lam","year":"2023","journal-title":"Adv. Mater."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.145501_bb1465","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jconrel.2005.06.014","article-title":"Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids","volume":"107","author":"Heyes","year":"2005","journal-title":"J. Control. Release"},{"issue":"34","key":"10.1016\/j.ijbiomac.2025.145501_bb1470","doi-asserted-by":"crossref","first-page":"8529","DOI":"10.1002\/anie.201203263","article-title":"Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo","volume":"51","author":"Jayaraman","year":"2012","journal-title":"Angew. Chem. Int. Edit."},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.145501_bb1475","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/mt.2013.124","article-title":"Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics","volume":"21","author":"Maier","year":"2013","journal-title":"Mol. Ther."},{"issue":"33","key":"10.1016\/j.ijbiomac.2025.145501_bb1480","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201606944","article-title":"Synthesis and biological evaluation of ionizable lipid materials for the in vivo delivery of messenger RNA to B lymphocytes","volume":"29","author":"Fenton","year":"2017","journal-title":"Adv. Mater."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.145501_bb1485","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27061943","article-title":"Modification of lipid-based nanoparticles: an efficient delivery system for nucleic acid-based immunotherapy","volume":"27","author":"Zhang","year":"2022","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb1490","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-27493-0","article-title":"An ionizable lipid toolbox for RNA delivery","volume":"12","author":"Han","year":"2021","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.145501_bb1495","doi-asserted-by":"crossref","first-page":"6571","DOI":"10.1021\/acsnano.4c18636","article-title":"Ionizable lipids with optimized linkers enable lung-specific, lipid nanoparticle-mediated mRNA delivery for treatment of metastatic lung tumors","volume":"19","author":"Naidu","year":"2025","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb1500","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/mt.2012.202","article-title":"Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines","volume":"21","author":"Pollard","year":"2013","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.145501_bb1505","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/infdis\/jiu522","article-title":"Potent immune responses in Rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion","volume":"211","author":"Bogers","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijbiomac.2025.145501_bb1510","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jconrel.2016.02.043","article-title":"Enhanced intranasal delivery of mRNA vaccine by overcoming the nasal epithelial barrier intra- and paracellular pathways","volume":"228","author":"Li","year":"2016","journal-title":"J. Control. Release"},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.145501_bb1515","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41434-019-0095-2","article-title":"Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA","volume":"26","author":"Blakney","year":"2019","journal-title":"Gene Ther."},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.145501_bb1520","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110514","article-title":"mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice","volume":"38","author":"Mu","year":"2022","journal-title":"Cell Rep."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.145501_bb1525","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1080\/01443615.2019.1634030","article-title":"Human papillomavirus and cervical cancer","volume":"40","author":"Okunade","year":"2020","journal-title":"J. Obstet. Gynaecol."},{"issue":"12 Pt 2","key":"10.1016\/j.ijbiomac.2025.145501_bb1530","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1016\/j.lpm.2014.10.001","article-title":"HPV in genital cancers (at the exception of cervical cancer) and anal cancers","volume":"43","author":"de Sanjose","year":"2014","journal-title":"Presse Med."},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.145501_bb1535","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1007\/s00262-021-03134-9","article-title":"Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16 cancer","volume":"71","author":"Salomon","year":"2022","journal-title":"Cancer Immunol Immun"},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.145501_bb1545","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.ymthe.2017.03.035","article-title":"Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses","volume":"25","author":"Bahl","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ijbiomac.2025.145501_bb1550","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-05482-0","article-title":"Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies","volume":"9","author":"Pardi","year":"2018","journal-title":"Nat. Commun."},{"issue":"6622","key":"10.1016\/j.ijbiomac.2025.145501_bb1555","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1126\/science.abm0271","article-title":"A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes","volume":"378","author":"Arevalo","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.ijbiomac.2025.145501_bb1560","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cytogfr.2022.10.001","article-title":"Development of mRNA vaccines against respiratory syncytial virus (RSV)","volume":"68","author":"Qiu","year":"2022","journal-title":"Cytokine Growth Factor Rev."},{"issue":"36","key":"10.1016\/j.ijbiomac.2025.145501_bb1565","doi-asserted-by":"crossref","first-page":"14604","DOI":"10.1073\/pnas.1209367109","article-title":"Nonviral delivery of self-amplifying RNA vaccines","volume":"109","author":"Geall","year":"2012","journal-title":"P Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb1570","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-020-0163-z","article-title":"Modified mRNA\/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection","volume":"5","author":"Espeseth","year":"2020","journal-title":"Npj Vaccines"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb1575","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54289-9","article-title":"A self-amplifying RNA RSV prefusion-F vaccine elicits potent immunity in pre-exposed and na\u00efve non-human primates","volume":"15","author":"Vijayan","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb1580","article-title":"A truncated pre-F protein mRNA vaccine elicits an enhanced immune response and protection against respiratory syncytial virus","volume":"16","author":"Lin","year":"2025","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.145501_bb1585","article-title":"Developments in rabies vaccines: the path traversed from Pasteur to the modern era of immunization","volume":"11","author":"Natesan","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb1590","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-39421-5","article-title":"Unmodified rabies mRNA vaccine elicits high cross-neutralizing antibody titers and diverse B cell memory responses (vol 14, 3713, 2023)","volume":"14","author":"Hellgren","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb1595","article-title":"A nucleoside-modified mRNA vaccine forming rabies virus-like particle elicits strong cellular and humoral immune responses against rabies virus infection in mice","volume":"13","author":"Liu","year":"2024","journal-title":"Emerg Microbes Infec"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb1600","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-025-01098-w","article-title":"Optimizing rabies mRNA vaccine efficacy via RABV-G structural domain screening and heterologous prime-boost immunization","volume":"10","author":"Li","year":"2025","journal-title":"Npj Vaccines"},{"issue":"27","key":"10.1016\/j.ijbiomac.2025.145501_bb1605","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"7830","key":"10.1016\/j.ijbiomac.2025.145501_bb1610","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb1615","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41541-022-00590-x","article-title":"A phase I\/II randomized, double-blinded, placebo-controlled trial of a self-amplifying Covid-19 mRNA vaccine","volume":"7","author":"Low","year":"2022","journal-title":"NPJ Vaccines"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.145501_bb1620","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1473-3099(21)00677-0","article-title":"Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b\/3 trial","volume":"22","author":"Kremsner","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.145501_bb1625","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41422-022-00626-w","article-title":"Rapid development of an updated mRNA vaccine against the SARS-CoV-2 omicron variant","volume":"32","author":"Zhang","year":"2022","journal-title":"Cell Res."},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.145501_bb1630","article-title":"Development of bivalent mRNA vaccines against SARS-CoV-2 variants","volume":"10","author":"Li","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ijbiomac.2025.145501_bb1635","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101262","article-title":"Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial","volume":"44","author":"Pollock","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.145501_bb1640","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/s41591-021-01527-y","article-title":"Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis","volume":"27","author":"Choi","year":"2021","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb1645","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2190690","article-title":"Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults","volume":"19","author":"Yassini","year":"2023","journal-title":"Hum. Vaccin. Immunother."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.145501_bb1650","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.106335","article-title":"Controllable self-replicating RNA vaccine delivered intradermally elicits predominantly cellular immunity","volume":"26","author":"Amano","year":"2023","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb1655","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41541-021-00324-5","article-title":"Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models","volume":"6","author":"Kalnin","year":"2021","journal-title":"NPJ Vaccines"},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.145501_bb1660","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1038\/s41564-022-01271-0","article-title":"Safety and immunogenicity of a prefusion non-stabilized spike protein mRNA COVID-19 vaccine: a phase I trial","volume":"7","author":"Gatechompol","year":"2022","journal-title":"Nat. Microbiol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.145501_bb1665","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abj9815","article-title":"Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B","volume":"8","author":"Liu","year":"2022","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb1670","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1038\/s41467-023-39376-7","article-title":"Safety and immunogenicity of a phase 1\/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis","volume":"14","author":"Lee","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb1675","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/aid.2017.0071","article-title":"Immunogenicity of AGS-004 dendritic cell therapy in patients treated during acute HIV infection","volume":"34","author":"Gay","year":"2018","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.ijbiomac.2025.145501_bb1680","author":"Arthur"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145501_bb1685","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/s13063-019-3409-1","article-title":"H.c. i, iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy","volume":"20","author":"de Jong","year":"2019","journal-title":"Trials"}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025060568?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025060568?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T02:03:25Z","timestamp":1770775405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813025060568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":331,"alternative-id":["S0141813025060568"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.145501","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancing mRNA vaccines: A comprehensive review of design, delivery, and efficacy in infectious diseases","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.145501","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"145501"}}